Abstracts tagged "pediatrics and treatment"

Abstract Number: 1438 • 2018 ACR/ARHP Annual Meeting
Treatment and Response of Down Syndrome Arthropathy
Jordan T. Jones¹, Nasreen Talib², Daniel J Lovell³ and Mara L Becker⁴, ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, ³Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Of the very few studies describing Down syndrome arthropathy (DA), crude prevalence estimates indicate DA maybe as common as juvenile idiopathic arthritis (JIA), however,…
Abstract Number: 380 • 2017 ACR/ARHP Annual Meeting
Treatment Outcomes of Down Syndrome Arthropathy
Jordan T. Jones¹, Leena Danawala², Nasreen Talib³ and Mara L Becker⁴, ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO, ³General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down syndrome arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].